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Background: Direct oral anticoagulants (DOACs) are now standard of care for the management of
thromboembolic risk. A prevalent issue of concern is how to manage direct oral anticoagulant (DOAC)-associated
bleeding for which there is no specific antidote available for clinical use. We conducted a retrospective case series
to describe the Toronto, Canada multicenter experience with bleeding from dabigatran or rivaroxaban.
Methods: Retrospective chart review of DOAC bleeding necessitating referral to hematology and/or transfusion
medicine services at five large University of Toronto affiliated academic hospitals from January 2011 to
December 2013.
Results: Twenty-six patients with DOAC bleeding were reviewed; 42 % bleeds intracranial and 50 %, gastrointestinal.
All patients had at least one risk factor associated with DOAC bleeding reported in previous studies. Inconsistent bleed
management strategies were evident. Median length of hospital stay was 11 days (1–90). Five thromboembolic events
occurred after transfusion based-hemostatic therapy and there were six deaths.
Conclusions: Management of DOAC bleeding is variable. Clinical trial data regarding DOAC reversal is needed to
facilitate optimization and standardization of bleeding treatment algorithms.
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Vitamin K antagonists have long been the mainstay of
prophylactic or therapeutic anticoagulation for thrombo-
embolism. The cumbersome disadvantages of warfarin
from both the patient and physician perspective have led
to the development, and now standard use, of direct oral
anticoagulants (DOACs) that do not require laboratory
monitoring and have fewer food and drug interactions.
Large clinical trials comparing the DOACs to vitamin
K antagonists have demonstrated similar efficacy in the
management and prevention of thromboembolism and
similar or reduced major bleeding rates [1–3]. As indica-
tions for DOACs expand, an issue of concern is how to
manage real-world DOAC-associated bleeding for which
no antidote is currently available. Guidelines and reviews
have extrapolated bleeding management principles from* Correspondence: sholzbergm@smh.ca
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[4–7]. Since no evidence-based, standard therapeutic al-
gorithm for DOAC bleeding is available, the primary ob-
jective of our study was to determine how patients are
currently being managed in this setting. We focused on
the experience with hemorrhage from dabigatran, a dir-
ect thrombin inhibitor, and rivaroxaban, a direct factor
Xa inhibitor, as apixaban, a direct factor Xa inhibitor,
was not yet approved for use in Canada.Methods
We conducted a retrospective chart review of DOAC
bleeding necessitating referral to hematology and/or
transfusion medicine services at five large University of
Toronto affiliated academic hospitals (St. Michael’s
Hospital, Toronto General Hospital, Toronto Western
Hospital, Sunnybrook Health Sciences Centre, Mount
Sinai Hospital) from January 2011 to December 2013.
Patients were included if they were: over the age of 18 years,
documented to have a DOAC associated hemorrhage andicle is distributed under the terms of the Creative Commons Attribution 4.0
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services.
The following data were abstracted from medical re-
cords: age and sex; body weight; DOAC type; indication
for DOAC; duration of time on DOAC therapy until
bleeding event (days); concomitant medication use; ini-
tial blood work (including complete blood cell count,
activated partial thromboplastin time (aPTT), pro-
thrombin time (PT), fibrinogen (Claus method), liver
enzymes (aspartate aminotransferase [AST], alanine
transaminase [ALT], alkaline phosphatase [ALP]), albu-
min, bilirubin, estimated creatinine clearance (Cockcroft-
Gault formula); description of bleeding episode (site, date/
time documented, red blood cell (RBC) transfusion, se-
verity of bleed – major or minor). Major bleeding was
defined according to the International Society on
Thrombosis and Haemostasis (ISTH)’s recommenda-
tions [8] as either involvement of a critical organ, fall
in haemoglobin of more than 20 g/L or requirement of
greater than two RBC transfusions. Of note, aforemen-
tioned data points included those known to be associ-
ated with increased risk of DOAC bleeding.
Additional data collected included: management of
bleeding (DOAC held, site compression, surgical man-
agement, fluids/adequate urine output, charcoal, haemo-
dialysis, transfusion [activated prothrombin complex
concentrate (aPCC), prothrombin complex concentrate
(PCC), activated recombinant factor VII, frozen plasma,
platelets, cryoprecipitate, fibrinogen concentrate] and
non-transfusion based [tranexamic acid, desmopressin,
vitamin K] hemostatic support; coagulation based test
results post-transfusion therapy; bleeding outcome (de-
crease, increase, no change, cessation); venous or arterial
thromboembolic (TE) event (with supportive imaging re-
sults and/or blood work); length of hospital stay; and
hospital discharge status (alive, dead).
Data were analyzed using descriptive statistics (mean,
median, range and standard deviation) and inferential
statistics (confidence interval). All analyses were per-
formed using SAS statistical software, version 9.2 (SAS
Institute Inc). Approval to perform this study and to re-
port the results was obtained from St Michael’s Hospital
Research Ethics Board, University Health Network Re-
search Ethics Board associated with Toronto General
Hospital and Toronto Western Hospital, the Human Re-
search Protections Program associated with Sunnybrook
Health Sciences Centre, and Mount Sinai Hospital Re-
search Ethics Board. The aforementioned list of research
ethics committees approved this study and granted ac-
cess to medical records and databases at their respective
hospital sites. Approval to publicize the data set was not
obtained by the hospital Research Ethics Boards. Hospi-
tals are required to protect the privacy of citizens whose
information they collect. The hospitals strive to complywith the Personal Health Information Protection Act
(PHIPA). Therefore data supporting the study findings
are unavailable.Results
Twenty-seven bleeding events were captured upon
retrospective review; one patient had two events hence a
total of 26 patients were reviewed. Nine bleeding events
occurred with rivaroxaban while 18 occurred with dabi-
gatran. All except four patients were over the age of
70 years with a median age of 78 years (range 52–
91 years). Approximately 69 % (18/26) of patients were
male. Three individuals were underweight (less than 60
kilograms) while the median weight was 78.3 (range 50–
150) kilograms. The median time taking the DOAC
prior to bleeding was 120 days (range 5–810). The indi-
cations for DOAC therapy included the following: atrial
fibrillation (n = 24), deep vein thrombosis (n = 1), and
two patients (7 %) treated for an off-label indication
(one for cancer associated pulmonary embolism and the
other for prophylaxis for an automated implantable
cardioverter-defibrillator. Of the nine rivaroxaban as-
sociated bleeds, five occurred at a dosage of 20 mg
daily and four at 15 mg daily. Of the 18 dabigatran
bleeds, eight occurred at a dosage of 150 mg twice per
day and ten at 110 mg twice per day. The median num-
ber of concomitant medications was 7 (range 1–16).
Five bleeding events occurred while the patient was
taking concomitant aspirin therapy, five events with
non-steroidal anti-inflammatory drugs (NSAIDs) and
three occurred with concomitant P-glycoprotein (P-gp)
inhibitors.
Eighty-nine percent of the bleeding events were classi-
fied as a major hemorrhage with 50 % requiring RBC
transfusion. Of those who were transfused with RBCs, a
median of 2.5 units (range 1–9) was required. Half of
the dabigatran patients were transfused with RBCs (me-
dian 3 units, range 1–3) compared to 44 % treated with
rivaroxaban (median 2 units, range 1–4).
Eleven (42 %) bleeding events were intracranial (ICH)
and 13 (50 %) were gastrointestinal (GI) in origin. Of
note, two of these events were combined ICH and GI
hemorrhages. Of the 13 GI hemorrhages, nine were as-
sociated with dabigatran use and four with rivaroxaban.
There were 11 ICH events, six occurred in dabigatran
users and five in rivaroxaban users. There was no statis-
tically significant association between dabigatran versus
rivaroxaban use and type of hemorrhage using a two-
tailed Fischer’s exact test (p = 0.68). More patients with
GI bleeds received RBC transfusion (62 %), as compared
to ICH (27 %).
The remaining four bleeds involved the following sites:
vaginal, pulmonary, subcutaneous or musculoskeletal with
Fig. 1 Bleed sites (N = 27 bleeding episodes in 26 patients)
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associated with a motor vehicle collision (Fig. 1).
Data were reviewed for risk factors (found in previous
observational studies) associated with DOAC bleeding.
In this study, all bleeding events occurred in the context
of at least one previously identified associating factor
and 63 % occurred with more than one. Specifically,
50 % of subjects were above 80 years of age and 33 % of
cases occurred with severe (<30 ml/min) or moderate
(30–50 ml/min) impairment in creatinine clearance at
time of bleeding. Five subjects had comorbid diabetes
mellitus, five were on concomitant aspirin and another
19 % were taking a NSAID (Table 1). Of the 26 patients,
14 were on a reduced dose of dabigatran (110 mg) or
rivaroxaban (15 mg). All of those patients were either of
older age or had impaired renal function. Fifty percent
of those on standard dose DOAC were older or had ab-
normal kidney function.Table 1 Risk factors associated with direct oral anticoagulant
bleeding
Clinical Variable Number of
patients
>80 years of age 12
Weight < 63 kg 4
Severe (<30 ml/min) or moderate (30–50 ml/min)





Concomitant strong P-gpb inhibitors 3
Higher than recommended dose of dabigatran 1
anon-steroidal anti-inflammatory drug
bp-glycoproteinOf the 18 dabigatran related bleed events (in 17 pa-
tients), five (28 %) received aPCC alone, two (11 %) re-
ceived aPCC and PCC, 13 (72 %) received at least one
hemostatic support of any kind and five (28 %) did not
receive any hemostatic therapy. Of the nine rivaroxaban
related bleeding events, six (67 %) received at least one
hemostatic support (two (22 %) received aPCC, two
(22 %) received PCC) and three (33 %) did not receive
any hemostatic therapy.
APCC tended to be administered to a larger number
of patients with ICH - six (54 %) - compared with iso-
lated GI hemorrhage - one (8 %). However, a similar
proportion of individuals received hemostatic therapy of
any kind (63 % for ICH and 69 % for GI bleed) (Table 2).
Hemostatic response to aPCC and/or PCC seemed to
differ according to the DOAC. Of the nine total patients
that received aPCC, three (all dabigatran related) had
resolution of bleeding within 12 to 24 h of administra-
tion. Of the five total patients that received PCC, one
bleed (rivaroxaban related) had resolution of bleeding at
24 h and there was no abnormal intra-operative bleeding
in another rivaroxaban related case. CBC, PT and aPTTTable 2 Hemostatic therapy according to bleed site
Intracranial Hemorrhage (ICH)
Events (N = 11) 2 combined ICH
and GIB
Gastrointestinal Bleed (GIB) Events
(N = 12) 2 combined ICH and GIB
6 (54 %) received aPCCa 1 (8 %) received aPCC
0 (0 %) received PCCb 2 (17 %) received PCC
2 (17 %) received both aPCC and
PCC
7 (64 %) received hemostatic
support of any kind
9 (75 %) received hemostatic
support of any kind
4 (36 %) did not receive
hemostatic therapy
3 (25 %) did not receive
hemostatic therapy
aactivated prothrombin complex concentrate
bprothrombin complex concentrate
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However, the frequency of repeated testing was highly
variable. Concise summarization of laboratory data was
not possible. Furthermore, we cannot comment on the
pattern of coagulation study normalization due to incon-
sistencies within the dataset.
There were five TE events in subjects who received
transfusion based hemostatic therapy (i.e. aPCC, PCC,
FP and/or platelets). All of the events were arterial in
nature involving either myocardial infarction or bowel
ischemia. A single arterial TE event occurred within
24 h of hemostatic transfusion (aPCC). There were no
TE events in patients who did not receive transfusion
based hemostatic therapy.
The median length of hospital stay was 11 days (range
1–90). There were six deaths (four dabigatran and two
rivaroxaban) (23 % of cases). The cause of death was
ICH in five patients and one death occurred secondary
to multi-organ failure and myocardial infarction. The
proportion of ICH resulting in death was 45 %.Discussion
We found, in this case series, that the management
of DOAC bleeding is highly variable. A large propor-
tion of patients in this study required prolonged
hospitalization and experienced TE complications. Add-
itionally, a substantial proportion of patients died. Of
interest, 33 % of the patients in this case series would not
have qualified for enrolment in the studies on the respect-
ive drugs.
This study is limited by the lack of control and de-
nominator data, however, it highlights the importance of
‘risk’ factors for major DOAC related bleeding namely,
advanced age, renal impairment, diabetes mellitus and
concomitant treatment with aspirin and NSAIDs [9–12].
Despite reassuring recent evidence from a meta-analysis
reviewing the bleeding rates in the elderly from pub-
lished randomized controlled trials comparing DOACs
with standard anticoagulant therapy, this study suggests
that careful patient selection for treatment with DOACs
remains paramount [12]. Interestingly, data from this
case series is in contrast to the recently published data
on rivaroxaban bleeding from the Dresden registry [13].
Most notably, this case series confirms that a high pro-
portion of patients who experience anticoagulant associ-
ated ICH die [14].Conclusion
In summary, this case series shows that there is consid-
erable variation in the treatment used to control DOAC
associated bleeding. This study also highlights the im-
portance of proper patient selection for DOAC therapy.
In conclusion, management of DOAC bleeding needs tobe optimized and standardized once clinical trial data
regarding reversal becomes available.
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